A clinical trial to study the effects of mumps-measles-rubella vaccine in improving patients with multiple warts in skin

Efficacy and safety of intralesional injection of mumps-measles-rubella (MMR) vaccine in the treatment of multiple cutaneous warts: a clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/10/010021

Enrollment

100

Registered

2017-10-06

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Multiple Cutaneous Warts

Interventions

Intervention1: mumps-measles-rubella (MMR) vaccine: 0.3 ml reconstituted mumps-measles-rubella (MMR) vaccine will be given intralesionally in the largest wart at 2 weeks interval for maximum 5 times C

Eligibility

Inclusion criteria

Inclusion criteria: i. Male or female patients with multiple warts who are candidate for treatment between 18 and 65 years of age (both inclusive). ii. Patients who give their informed consent.

Exclusion criteria

Exclusion criteria: i. Pregnant and lactating women. ii. Any evidence of immunosuppression (eg. HIV infection, organ transplantation, long term steroid use etc.). iii. Any other systemic disease (eg. liver or kidney disorder). iv. Presence of mucosal wart(s). v. Presence of ulcerated or inflamed wart(s).

Design outcomes

Primary

Measure	Time frame
number of visible warts on the skinTimepoint: 12 weeks	—

Secondary

Measure	Time frame
the number of patients showing complete resolution of wartsTimepoint: 12 weeks	—

Countries

India

Contacts

Public ContactDr Ankur Ghosh

Guide

sschaudhary123@gmail.com9431186554

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026